Focused On-demand Library for Signal peptide peptidase-like 2A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCT8

UPID:

SPP2A_HUMAN

Alternative names:

Intramembrane protease 3; Presenilin-like protein 2

Alternative UPACC:

Q8TCT8; B2RDS0; Q8TAW1; Q96SZ8

Background:

Signal peptide peptidase-like 2A, also known as Intramembrane protease 3 or Presenilin-like protein 2, plays a pivotal role in immune system regulation. It functions as an intramembrane-cleaving aspartic protease, involved in the processing of FASLG, ITM2B, and TNF. This protein is essential for the degradation of CD74, crucial for antigen-presenting cells, and participates in the cleavage of the simian foamy virus envelope glycoprotein gp130.

Therapeutic significance:

Signal peptide peptidase-like 2A's involvement in Immunodeficiency 86, a disorder marked by increased susceptibility to mycobacterial diseases, underscores its therapeutic potential. Targeting this protein could lead to innovative treatments for immune system disorders, particularly those related to vaccine responses.